You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Low Annexin A1 expression predicts benefit from induction chemotherapy in oral cancer patients with moderate or poor pathologic differentiation grade
|
|---|---|
| Published in |
BMC Cancer, June 2013
|
| DOI | 10.1186/1471-2407-13-301 |
| Pubmed ID | |
| Authors |
Dong-wang Zhu, Ying Liu, Xiao Yang, Cheng-zhe Yang, Jie Ma, Xi Yang, Jin-ke Qiao, Li-zhen Wang, Jiang Li, Chen-ping Zhang, Zhi-yuan Zhang, Lai-ping Zhong |
| Abstract |
The benefit of induction chemotherapy in locally advanced oral squamous cell carcinoma (OSCC) remains to be clearly defined. Induction chemotherapy is likely to be effective for biologically distinct subgroups of patients and biomarker development might lead to identification of the patients whose tumors are to respond to a particular treatment. Annexin A1 may serve as a biomarker for responsiveness to induction chemotherapy. The aim of this study was to investigate Annexin A1 expression in pre-treatment biopsies from a cohort of OSCC patients treated with surgery and post-operative radiotherapy or docetaxel, cisplatin and 5-fluorouracil (TPF) induction chemotherapy followed by surgery and post-operative radiotherapy. Furthermore we sought to assess the utility of Annexin A1 as a prognostic or predictive biomarker. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 1 | 50% |
| Practitioners (doctors, other healthcare professionals) | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 47 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 2% |
| Netherlands | 1 | 2% |
| France | 1 | 2% |
| Unknown | 44 | 94% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 9 | 19% |
| Student > Bachelor | 7 | 15% |
| Student > Postgraduate | 5 | 11% |
| Other | 4 | 9% |
| Student > Ph. D. Student | 4 | 9% |
| Other | 9 | 19% |
| Unknown | 9 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 16 | 34% |
| Biochemistry, Genetics and Molecular Biology | 7 | 15% |
| Agricultural and Biological Sciences | 6 | 13% |
| Nursing and Health Professions | 2 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 2% |
| Other | 3 | 6% |
| Unknown | 12 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 June 2013.
All research outputs
#14,754,618
of 22,712,476 outputs
Outputs from BMC Cancer
#3,665
of 8,264 outputs
Outputs of similar age
#117,427
of 196,834 outputs
Outputs of similar age from BMC Cancer
#47
of 80 outputs
Altmetric has tracked 22,712,476 research outputs across all sources so far. This one is in the 32nd percentile – i.e., 32% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,264 research outputs from this source. They receive a mean Attention Score of 4.3. This one has gotten more attention than average, scoring higher than 50% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 196,834 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 38th percentile – i.e., 38% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 80 others from the same source and published within six weeks on either side of this one. This one is in the 33rd percentile – i.e., 33% of its contemporaries scored the same or lower than it.